Genentech reiterated by Merrill Lynch at buy

Genentech Inc. was maintained by Merrill Lynch analyst Eric Ende at a buy rating with a price target on the stock of $100 per share following news of its plan to file approval for the eye treatment Lucentis in December without fast-track status. Genentech shares Thursday were down $0.91, or 0.99%, at $91.20 on volume of 3,688,800 shares versus the three-month running average of 3,386,900 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.